Please ensure Javascript is enabled for purposes of website accessibility
Maxx Chatsko

Maxx Chatsko


Maxx has been a contributor to since 2013. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering.

Recent articles

chalkboard stock down pink

Here's Why Minerva Neurosciences Collapsed Today

The company's lead drug candidate flopped in a phase 3 trial. Can a longer-term follow-up study resurrect the asset?

businessman rocket

Here's Why Arcus Biosciences Stock Gained as Much as 15.9% Today

The development-stage biopharma is bouncing back from a recent stock dip.

arrow up shelves

Here's Why Agenus Rose as Much as 23.3% Today

The biopharma company provided a clinical update for an important pipeline asset.

309 corn harvest birds eye

Is Green Plains a Buy?

The renewable fuel company's stock crashed when governments restricted movement to fight the coronavirus pandemic. Can it recover just as quickly?

stock down erased chalkboard

Iovance Biotherapeutics Couples Data Release With Stock Offering

The biotech company is looking to raise up to $575 million ahead of its transition to commercial-stage operations.

023 stock questions chalkboard

Is Axsome Therapeutics a Buy?

The pharmaceutical company appears poised to earn multiple regulatory approvals in 2021. But has too much anticipated success already been priced into its shares?

025 question mark on table

Is Coherus BioSciences a Buy?

The biosimilar leader has found quick success with its first major drug product, but the stock's performance hasn't seemed to reflect that.

business growth

Is Arrowhead Pharmaceuticals a Buy?

The development-stage genetic medicine company is eager to convert its intriguing potential into tangible progress.

534 question cards wooden box

Should Codexis Investors Prepare for Slower Growth?

The company's largest source of revenue will be affected by the pandemic, but there appears to be a silver lining.

dude tossing stacks

The Case Against Enphase Energy's $200 Million Share Repurchase Program

Shares are at an all-time high and trading at a historic premium. A stock-buyback program could be a terrible use of cash for the high-growth business.

paper airplanes rising

Here's Why Green Plains Roared Higher Today

An analyst upgraded the stock after seeing signs of a recovery in ethanol markets. Investors might not be as enthusiastic.

079 wind turbines hill

The Coronavirus Pandemic Is Accelerating the Energy Transition

Energy-related carbon emissions will fall by a record amount in 2020, but a surprising amount of the gains could prove permanent once the economy rebounds.

302 yellow arrow oppose

The Coronavirus Pandemic Is a Big Headwind for Albemarle

The most significant effects might not be felt until the second half of 2020, but investors might expect them to weigh on the dividend stock for the foreseeable future.

272 dominos falling stop

Is Another Accounting Issue Brewing for Amyris?

Investors are less than two years removed from a significant accounting discrepancy. A closer look at SEC filings reveals another potential cause for concern.

arrow up shelves

Here's Why Silver Stocks Rose Today

A steady stream of souring economic data is driving gold and silver prices higher.

woman orange laptop excited

Here's Why Allogene Therapeutics Is Roaring Higher Today

The development-stage biopharma reported encouraging, albeit early, data from an important pipeline program.

600 businessman winning

Is Amyris Finally Turning a Corner?

Investors were pleased by relatively positive operating results in the first quarter of 2020. Can the synthetic biology company turn those results into a durable trend?

multiple lines up

Here's Why Mesoblast Is Soaring Today

The business raised new capital to ready for the next phase of expansion.

046 dna model

Invitae Readies Telemedicine Marketing Blitz as Testing Volumes Fall 50%

The company thinks a post-pandemic world will appreciate the need for genetic information more than before, but Invitae must navigate uncertainty in the meantime.

woman orange laptop excited

Repligen Bucks Industry Trend, Increases Full-Year 2020 Guidance

The bioprocess equipment leader didn't see a slowdown from the coronavirus pandemic, while expected headwinds in a major business unit failed to materialize.